Display Settings:

Format
Items per page
Sort by
  • Reverse

Send to:

Choose Destination

Results: 1 to 10 of 36

1.

Reversion of the ErbB malignant phenotype and the DNA damage response.

Runkle EA, Zhang H, Cai Z, Zhu Z, Karger BL, Wu SL, O'Rourke DM, Zhou Z, Wang Q, Greene MI.

Exp Mol Pathol. 2012 Dec;93(3):324-33. doi: 10.1016/j.yexmp.2012.09.007. Epub 2012 Sep 27. Review.

PubMed [citation]
PMID:
23022358
PMCID:
PMC3518600
2.

Structural insights into SUN-KASH complexes across the nuclear envelope.

Wang W, Shi Z, Jiao S, Chen C, Wang H, Liu G, Wang Q, Zhao Y, Greene MI, Zhou Z.

Cell Res. 2012 Oct;22(10):1440-52. doi: 10.1038/cr.2012.126. Epub 2012 Sep 4.

PubMed [citation]
PMID:
22945352
PMCID:
PMC3463262
3.

Structural and biological features of FOXP3 dimerization relevant to regulatory T cell function.

Song X, Li B, Xiao Y, Chen C, Wang Q, Liu Y, Berezov A, Xu C, Gao Y, Li Z, Wu SL, Cai Z, Zhang H, Karger BL, Hancock WW, Wells AD, Zhou Z, Greene MI.

Cell Rep. 2012 Jun 28;1(6):665-75. doi: 10.1016/j.celrep.2012.04.012. Epub 2012 Jun 15.

PubMed [citation]
PMID:
22813742
PMCID:
PMC3401381
4.

YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14.

Huang JM, Nagatomo I, Suzuki E, Mizuno T, Kumagai T, Berezov A, Zhang H, Karlan B, Greene MI, Wang Q.

Oncogene. 2013 Apr 25;32(17):2220-9. doi: 10.1038/onc.2012.231. Epub 2012 Jun 11.

PubMed [citation]
PMID:
22689061
PMCID:
PMC3443515
5.

The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer.

McKie AB, Vaughan S, Zanini E, Okon IS, Louis L, de Sousa C, Greene MI, Wang Q, Agarwal R, Shaposhnikov D, Wong JL, Gungor H, Janczar S, El-Bahrawy M, Lam EW, Chayen NE, Gabra H.

Cancer Discov. 2012 Feb;2(2):156-71. doi: 10.1158/2159-8290.CD-11-0256.

PubMed [citation]
PMID:
22585860
PMCID:
PMC3378039
6.

Structure of Sad1-UNC84 homology (SUN) domain defines features of molecular bridge in nuclear envelope.

Zhou Z, Du X, Cai Z, Song X, Zhang H, Mizuno T, Suzuki E, Yee MR, Berezov A, Murali R, Wu SL, Karger BL, Greene MI, Wang Q.

J Biol Chem. 2012 Feb 17;287(8):5317-26. doi: 10.1074/jbc.M111.304543. Epub 2011 Dec 14.

PubMed [citation]
PMID:
22170055
PMCID:
PMC3285312
7.

Disabling the mitotic spindle and tumor growth by targeting a cavity-induced allosteric site of survivin.

Berezov A, Cai Z, Freudenberg JA, Zhang H, Cheng X, Thompson T, Murali R, Greene MI, Wang Q.

Oncogene. 2012 Apr 12;31(15):1938-48. doi: 10.1038/onc.2011.377. Epub 2011 Sep 5.

PubMed [citation]
PMID:
21892210
PMCID:
PMC3570121
8.

The feasibility of Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma.

Inoda S, Morita R, Hirohashi Y, Torigoe T, Asanuma H, Nakazawa E, Nakatsugawa M, Tamura Y, Kamiguchi K, Tsuruma T, Terui T, Ishitani K, Hashino S, Wang Q, Greene MI, Hasegawa T, Hirata K, Asaka M, Sato N.

Exp Mol Pathol. 2011 Feb;90(1):55-60. doi: 10.1016/j.yexmp.2010.10.001. Epub 2010 Oct 13.

PubMed [citation]
PMID:
20950610
9.

Targeting erbB receptors.

Cai Z, Zhang H, Liu J, Berezov A, Murali R, Wang Q, Greene MI.

Semin Cell Dev Biol. 2010 Dec;21(9):961-6. doi: 10.1016/j.semcdb.2010.09.005. Epub 2010 Sep 17. Review.

PubMed [citation]
PMID:
20850557
10.

Suppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid marker.

Zhang G, Zhang H, Wang Q, Lal P, Carroll AM, de la Llera-Moya M, Xu X, Greene MI.

Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):732-7. doi: 10.1073/pnas.0911397107. Epub 2009 Dec 18.

PubMed [citation]
PMID:
20080743
PMCID:
PMC2818935